Speciality Medicines Ltd vs Zydus Lifesciences Limited

A side-by-side comparison of Speciality Medicines Ltd (544738) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

Speciality Medicines Ltd vs Zydus Lifesciences Limited are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.

  • Valuation22
  • Profitability22
  • Growth20
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

10.11
P/E ratio
22.42
0.00
P/B ratio
4.11
0.00%
Dividend yield
0.09%
₹14.83
EPS
₹50.09

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

25.60%
Return on equity
18.59%
25.00%
Return on capital
18.07%
18.00%
EBITDA margin
31.22%
17.33%
Net margin
18.87%

Growth

544738 takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

48.29%
Revenue CAGR (3Y)
16.35%
86.63%
Profit CAGR (3Y)
34.80%

Size & financial health

ZYDUSLIFE takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.12L Cr
₹75 Cr
Revenue
₹27,148 Cr
₹13 Cr
Net profit
₹5,124 Cr
0.00
Debt / equity
0.46
Speciality Medicines Ltd
  • + ["Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%"]
  • − ["Though the company is reporting repeated profits, it is not paying out dividend", "Tax rate seems low"]
Zydus Lifesciences Limited
  • + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
  • − []
Speciality Medicines Ltd full analysis Zydus Lifesciences Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.